Supernus Pharmaceuticals (LTS:0LB2) Cyclically Adjusted Book per Share: $13.93 (As of Mar. 2026)


LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
88 GF Score
Price $46.89
GF Value $40.98
Valuation Modestly Overvalued
View Full Analysis

What is Supernus Pharmaceuticals Cyclically Adjusted Book per Share?

Supernus Pharmaceuticals LTS:0LB2 +0.82% 88 Cyclically Adjusted Book per Share is $13.93 as of Mar. 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $40.98 (Modestly Overvalued).

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $18.553. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $13.93 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Supernus Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 15.80% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 19.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 24.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Supernus Pharmaceuticals was 37.50% per year. The lowest was 19.10% per year. And the median was 26.20% per year.

As of today (2026-07-01), Supernus Pharmaceuticals's current stock price is $46.8901. Supernus Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $13.93. Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 3.37.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Supernus Pharmaceuticals was 7.69. The lowest was 2.33. And the median was 3.98.


Supernus Pharmaceuticals  (LTS:0LB2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=46.8901/13.93
=3.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Supernus Pharmaceuticals was 7.69. The lowest was 2.33. And the median was 3.98.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Supernus Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Supernus Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals Cyclically Adjusted Book per Share Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.45 8.19 10.28 12.10 14.19

Supernus Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.41 13.00 13.56 14.19 13.93

LTS:0LB2 vs BCRX, PBH, RGC: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


LTS:0LB2
88GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Supernus Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=18.553/330.2130*330.2130
=18.553

Current CPI (Mar. 2026) = 330.2130.

Supernus Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.848 241.018 3.902
201609 3.500 241.428 4.787
201612 3.837 241.432 5.248
201703 4.103 243.801 5.557
201706 4.522 244.955 6.096
201709 4.909 246.819 6.568
201712 5.213 246.524 6.983
201803 6.815 249.554 9.018
201806 7.484 251.989 9.807
201809 8.074 252.439 10.562
201812 8.659 251.233 11.381
201903 9.165 254.202 11.906
201906 9.970 256.143 12.853
201909 10.622 256.759 13.661
201912 11.334 256.974 14.564
202003 11.675 258.115 14.936
202006 12.655 257.797 16.210
202009 13.459 260.280 17.075
202012 14.089 260.474 17.861
202103 14.236 264.877 17.748
202106 14.782 271.696 17.966
202109 15.240 274.310 18.346
202112 15.319 278.802 18.144
202203 15.518 287.504 17.823
202206 15.730 296.311 17.530
202209 15.777 296.808 17.553
202212 16.334 296.797 18.173
202303 16.746 301.836 18.320
202306 16.850 305.109 18.236
202309 16.697 307.789 17.913
202312 16.840 306.746 18.128
202403 16.905 312.332 17.873
202406 17.394 314.175 18.282
202409 18.239 315.301 19.102
202412 18.581 315.605 19.441
202503 18.409 319.799 19.008
202506 18.958 322.561 19.408
202509 18.377 324.800 18.683
202512 18.478 324.054 18.829
202603 18.553 330.213 18.553

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $13.93 mean?
Supernus Pharmaceuticals (LTS:0LB2) has a Cyclically Adjusted Book per Share of $13.93 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Supernus Pharmaceuticals' current Cyclically Adjusted Book per Share is $13.93. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' Cyclically Adjusted Book per Share compare to BCRX and PBH?
Supernus Pharmaceuticals' Cyclically Adjusted Book per Share of $13.93 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current Cyclically Adjusted Book per Share is $13.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.98, compared to a current price of $46.89 — trading 14.4% above its estimated fair value. The current Cyclically Adjusted Book per Share is $13.93. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current Cyclically Adjusted Book per Share is $13.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued. The current stock price of $46.89 is trading 14.4% above its estimated GF Value™ of $40.98. GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for LTS:0LB2:

  • Cyclically Adjusted Book per Share: $13.93
  • GF Value™: $40.98 vs. price of $46.89 (14.4% above fair value)
  • GF Score™: 88/100

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score

Get the complete analysis for LTS:0LB2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$46.89
Price
$40.98
GF Value